CLINICAL TRIALS PROFILE FOR TRIFLUOPERAZINE HYDROCHLORIDE

All Clinical Trials for TRIFLUOPERAZINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01765829 ↗	Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis	Unknown status	Instituto de Salud Carlos III	Phase 3	2012-11-01	The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed a discontinuation treatment scheme based in the presence of prodromes. The candidates should accomplish the following criteria: first episode of non-affective psychosis who have followed antipsychotic treatment for 12 months and who have already shown remission criteria.
NCT01765829 ↗	Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis	Unknown status	Fundación Pública Andaluza Progreso y Salud	Phase 3	2012-11-01	The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed a discontinuation treatment scheme based in the presence of prodromes. The candidates should accomplish the following criteria: first episode of non-affective psychosis who have followed antipsychotic treatment for 12 months and who have already shown remission criteria.
NCT02582736 ↗	Antipsychotics and Risk of Hyperglycemic Emergencies	Completed	Canadian Institutes of Health Research (CIHR)		2012-04-01	The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02582736 ↗	Antipsychotics and Risk of Hyperglycemic Emergencies	Completed	Drug Safety and Effectiveness Network, Canada		2012-04-01	The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02582736 ↗	Antipsychotics and Risk of Hyperglycemic Emergencies	Completed	Canadian Network for Observational Drug Effect Studies, CNODES		2012-04-01	The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02600741 ↗	Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)	Completed	Janssen Scientific Affairs, LLC		2015-07-24	The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization, psychiatric emergency room (ER) visit, crisis center visit, mobile crisis unit intervention, arrest/incarceration, and suicide or suicide attempt) in patients under their care during a 12 month period.
NCT02704962 ↗	Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine	Completed	Department of Health, Executive Yuan, R.O.C. (Taiwan)	Phase 4	2012-01-01	The investigators hypothesis is that an antipsychotic drug combination of low-dose olanzapine plus low-dose trifluoperazine is similar to regular-dose olanzapine monotherapy in efficacy and safety for treatment of schizophrenia.The goal of this study is to compare the efficacy and safety of the olanzapine (10 mg/d) and olanzapine (5 mg/d) plus trifluoperazine (5 mg/d) in the treatment of acute psychotic exacerbations of schizophrenia.

Clinical Trial Conditions for TRIFLUOPERAZINE HYDROCHLORIDE

Condition Name

Condition Name for TRIFLUOPERAZINE HYDROCHLORIDE
Intervention	Trials
Schizophrenia	3
Bipolar Disorder	2
Psychosis Nos/Other	1
Psychotic Disorders	1

Condition MeSH

Condition MeSH for TRIFLUOPERAZINE HYDROCHLORIDE
Intervention	Trials
Schizophrenia	3
Bipolar Disorder	2
Psychotic Disorders	2
Mental Disorders	2

Clinical Trial Locations for TRIFLUOPERAZINE HYDROCHLORIDE

Trials by Country

Trials by Country for TRIFLUOPERAZINE HYDROCHLORIDE
Location	Trials
United States	25
Spain	9
Canada	1
China	1
Taiwan	1

Trials by US State

Trials by US State for TRIFLUOPERAZINE HYDROCHLORIDE
Location	Trials
Ohio	2
New York	2
New Hampshire	1
Missouri	1
Michigan	1

Clinical Trial Progress for TRIFLUOPERAZINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for TRIFLUOPERAZINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	1
Phase 3	1

Clinical Trial Status

Clinical Trial Status for TRIFLUOPERAZINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	3
Unknown status	2
Recruiting	2

Clinical Trial Sponsors for TRIFLUOPERAZINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for TRIFLUOPERAZINE HYDROCHLORIDE
Sponsor	Trials
Kaohsiung Kai-Suan Psychiatric Hospital	1
Lindner Center of HOPE	1
Alphacait, LLC	1

Sponsor Type

Sponsor Type for TRIFLUOPERAZINE HYDROCHLORIDE
Sponsor	Trials
Other	12
Industry	1

TRIFLUOPERAZINE HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: April 27, 2026

Trifluoperazine Hydrochloride: Clinical-Trial Update, Market Read, and Projection

What is trifluoperazine hydrochloride in the drug landscape?

Trifluoperazine hydrochloride (a first-generation typical antipsychotic; phenothiazine class) is an established, off-patent product in most jurisdictions. Commercial supply is concentrated in generic and authorized branded formulations, with clinical development activity driven less by patentable “new entrants” and more by label-specific work, formulation changes, safety updates, and guideline-adjacent studies.

Key positioning drivers:

• Use profile: schizophrenia and other psychotic disorders; also used in some settings for anxiety/behavioral indications depending on local labeling.
• Competition: broad typical antipsychotic and second-generation antipsychotic alternatives, including long-acting injectables and newer oral options.
• Innovation pathway: where new studies appear, they typically target safety, tolerability, adherence, and dosing regimens rather than new molecular entities.

---

What does the current clinical-trial pipeline look like?

No consolidated, continuously updated, single-source pipeline exists in open literature for trifluoperazine across all regions. Published trial activity for older, off-patent antipsychotics is often sparse, smaller in scale, and not consistently captured unless the study is registered and published in major databases.

Practical read-through for decision-making

• Expect low volume of late-stage trials for the active substance itself in 2024-2026.
• Expect more activity in observational studies, real-world safety work, and comparative effectiveness work where trifluoperazine appears as a comparator.
• Expect limited “registration-enabling” development unless a sponsor is pursuing a jurisdiction-specific label expansion, a new formulation, or bioavailability/bridging work.

Clinical trial search reality (business takeaway) For an off-patent, first-generation antipsychotic with broad generic coverage, the market usually does not reward large Phase 3 programs. When studies surface, the commercial logic typically aligns with:

• local regulatory requirements for generics,
• post-marketing pharmacovigilance,
• pharmacokinetic bridging for a reformulated product.

---

What is the market structure for trifluoperazine hydrochloride?

Market demand type

• Steady, price-sensitive demand tied to managed care formularies, guideline adherence, and clinician familiarity.
• Low willingness to pay for incremental improvements unless a product solves a supply, stability, or administration issue.

Supply type

• Generic-led: multiple manufacturers compete on price, bioequivalence, and availability.
• Formulation breadth: oral tablets dominate; local variants depend on each country’s registered strengths and packaging.

Competitive set

• Typical antipsychotics: comparable low-cost options.
• Second-generation antipsychotics: higher-cost alternatives that can displace typicals when payers and clinicians prioritize metabolic profile and tolerability.

---

How does pricing and penetration typically behave?

For off-patent first-generation antipsychotics:

• Unit prices trend to the floor in high-inventory markets.
• Volume stays stable where formularies maintain at least one typical antipsychotic.
• Switching risk rises when second-generation agents are covered or when local prescribing practices favor atypicals.

---

What is the forward-looking market projection?

Projection approach for an off-patent, generic-heavy molecule A defensible projection requires triangulating multiple inputs (sales histories, filings, procurement data, and tender outcomes). Without an internal dataset, the most actionable external projection is range-based and structurally driven:

Base-case projection (directional)

• Global category growth: low to moderate, driven by population needs and payer formularies rather than new adoption.
• Molecule share: likely stable to slightly down where atypicals expand.
• Revenue: can remain flat to mildly down in real terms due to ongoing generic price pressure, with occasional offsets from supply stabilization or tender-driven cycles.

Three-scenario view (2016-2026-style behavior for generic CNS products)

Scenario	Molecule unit demand	Pricing pressure	Revenue outcome
Bear	Flat to down	High	Mild decline
Base	Flat to slightly up	Moderate	Flat to mild decline
Bull	Up modestly	Lower	Flat to mild growth

What matters most to the numbers

• payer policy shifts between typical and atypical antipsychotics,
• procurement tender dynamics,
• and whether the molecule remains on key formulary lists.

---

Where can “value creation” still happen?

If trifluoperazine is the target, commercial upside usually comes from execution rather than molecule innovation:

1. Formulation and manufacturing continuity
   • tighter compliance and stable supply reduce stockouts and tender losses.
2. Regulatory coverage breadth
   • sustaining registrations across strengths and dosage forms supports continuity of demand.
3. Value-based contracting
   • winning procurement where payers prefer low acquisition cost typicals.
4. Line extension packaging
   • targeting institutional buyers with reliable dosing formats.

---

Regulatory and evidence posture (what typically supports product survival)

For older generics, the “clinical evidence” burden is usually satisfied by:

• bioequivalence to a reference product,
• safety literature and post-marketing reporting,
• and labeling compliance with jurisdiction-specific requirements.

---

Key Takeaways

• Trifluoperazine hydrochloride is an off-patent typical antipsychotic with market supply dominated by generics and limited incentive for large late-stage clinical programs on the active molecule.
• Current clinical-trial activity is expected to be sparse and skewed toward observational or comparator roles, with most development value tied to formulation or regulatory bridging rather than new efficacy.
• Market outlook is structurally stable but exposed to ongoing generic price pressure and possible share loss versus second-generation antipsychotics as payer coverage and clinical preference shift.
• Near-term business outcomes will hinge on procurement execution, formulation/manufacturing reliability, and maintaining broad regulatory coverage.

---

FAQs

1) Is trifluoperazine hydrochloride still actively developed in large clinical programs?
Typically not at scale; activity for off-patent older antipsychotics is usually limited and often not late-stage molecule-defining.

2) What type of studies most commonly involve trifluoperazine today?
Observational safety/effectiveness work, comparative studies, and sometimes pharmacokinetic or formulation bridging for generic/regulatory needs.

3) How does the competitive landscape affect pricing?
Generic competition drives pricing toward acquisition-cost minimization, with volume supported by formulary inclusion and tender awards.

4) What is the biggest market risk over the next 3 to 5 years?
Share dilution if formularies shift further toward second-generation antipsychotics and long-acting options, combined with sustained generic price pressure.

5) Where can a new entrant win commercially?
Reliability of supply, regulatory breadth, and cost-competitive tender positioning rather than new clinical efficacy claims.

---

References

[1] U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] World Health Organization. ATC/DDD Index. https://www.whocc.no/atc_ddd_index/
[3] ClinicalTrials.gov. Trifluoperazine Hydrochloride: Studies. https://clinicaltrials.gov/